You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Original article
Spectral-domain OCT peripapillary retinal nerve fibre layer thickness measurements in patients with stargardt disease
  1. Mohamed A Genead,
  2. Gerald A Fishman,
  3. Anastasios Anastasakis
  1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
  1. Correspondence to Dr Gerald A Fishman, Department of Ophthalmology and Visual Sciences (MC 648), Room 3.85, Eye and Ear Infirmary, 1855W Taylor Street, Chicago, IL 60612-7234, USA; gerafish{at}uic.edu

Abstract

Aims To evaluate the presence of peripapillary retinal nerve fibre layer (RNFL) defects in patients with Stargardt disease by using spectral-domain optical coherence tomography (SD-OCT).

Methods Fifty-two eyes of 27 patients with Stargardt disease underwent peripapillary RNFL thickness measurements using SD-OCT.

Results Twenty-seven patients with Stargardt disease were enrolled. Their mean (±SD) age was 38.3 (14.7) years. Fourteen patients (51.9%) showed a thinning of the peripapillary RNFL in one or more quadrants in at least one eye, and four patients (14.8%) in both eyes. Five patients (18.5%) showed a thickening of the peripapillary RNFL in at least one eye, and four patients (14.8%) in both eyes.

Conclusion This study demonstrated the presence of defects in the peripapillary RNFL thickness in patients with Stargardt disease by using SD-OCT. It would be clinically prudent that Stargardt patients considered for various treatment options be considered for RNFL thickness measurements.

  • Stargardt disease
  • peripapillary retinal nerve fibre layer
  • Spectral-domain OCT
  • retina
  • dystrophy
  • imaging

http://dx.doi.org/10.1136/bjo.2010.189720

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding Supported by funds from the Foundation Fighting Blindness, Owings Mills, Maryland; Grant Healthcare Foundation, Lake Forest, Illinois; NIH core grant EYO1792; and an unrestricted departmental grant from Research to Prevent Blindness.

    • Patient consent Obtained.

    • Ethics approval Ethics approval was provided by an institutional review board at the University of Illinois and the University of Illinois ethics committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.